By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Start-up Blueprint Medicines today announced it has closed on a $40 million Series A round.

The round was led by Third Rock Ventures, and proceeds will be used to develop new cancer therapies using Blueprint's proprietary compound library and Insights-to-Validation platform that targets molecular drivers of cancer "and emerging resistance mechanisms unique to certain cancer patients," the firm said.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

The Washington Post reports on a Federal Bureau of Investigation plan to place rapid DNA analyzers at booking stations around the country.

In an editorial, officials from scientific societies in the US and China call for the international community to develop criteria and standards for human germline editing.

The US National Institutes of Health is to review studies that have received private support for conflicts of interest, according to the New York Times.

In Science this week: the PsychENCODE Consortium reports on the molecular mechanisms of neuropsychiatric disorders, and more.